🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: NEPA

Found 16 matching trials

A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients

PHASE4

This study was a multicenter, prospective, controlled trial involving 120 b...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2025-12-15

Trial ID

NCT07254416

Treatments Being Tested

NEPA Dexamethasone Megestrol Acetate

NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

N/A

This clinical trial is a prospective, observational, multicenter cohort stu...

Status

Enrolling By Invitation

Location

Samsung Medical Center

Start Date

2025-08-12

Trial ID

NCT07132749

Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

PHASE4

MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receivi...

Status

Completed

Location

Shanghai Chest Hospital

Start Date

2021-02-01

Trial ID

NCT04817189

Treatments Being Tested

NEPA (300mg netupitant/0.5mg palonosetron)Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)Dexamethasone, 8 mg (oral) or equivalent IV dose

Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients

PHASE4

This pragmatic trial addresses the clinical gap through the generation of e...

Status

Unknown

Location

CHU Avicenne

Start Date

2018-09-19

Trial ID

NCT03831633

Treatments Being Tested

Akynzeo Standard of Care

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

PHASE2

This phase II trial studies how well netupitant and palonosetron hydrochlor...

Status

Completed

Location

OHSU Knight Cancer Institute

Start Date

2017-04-27

Trial ID

NCT03097588

Treatments Being Tested

Netupitant Palonosetron Hydrochloride Questionnaire Administration

Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin

PHASE3

This study evaluates the possibility to reduce the total dose of dexamethas...

Status

Unknown

Location

ASST Bergamo Ovest - Ospedale di Teviglio

Start Date

2016-11-25

Trial ID

NCT04201769

Treatments Being Tested

Netupitant/Palonosetron Dexamethasone

NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer

PHASE2

This study evaluates if the activity of one-day of NEPA plus dexamethasone,...

Status

Completed

Location

Multiple Locations

Start Date

2016-05-12

Trial ID

NCT03862144

Treatments Being Tested

Netupitant/Palonosetron

Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults

This study will evaluate the feasibility and efficacy of combining a tradit...

Status

Completed

Location

UF Clinical Translational Research Building

Start Date

2016-04

Trial ID

NCT02632487

Treatments Being Tested

Exercise Non-Exercise Physical Activity (NEPA)

Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)

PHASE2

Chemotherapy often causes nausea and vomiting (CINV), and this is a major p...

Status

Recruiting

Location

Aghia Sophia Children's Hospital, Pediatric Hematology/ Oncology Unit (POHemU)

Start Date

2025-07-07

Trial ID

NCT06904235

Treatments Being Tested

IV NEPA (fosnetupitant/palonosetron)Reference Treatment: IV ondansetron infusion Reference Treatment: IV fosaprepitant infusion

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

PHASE3

The objective of this Prospective, randomized, non inferiority phase III tr...

Status

Completed

Location

Fudan University Shanghai Cancer Cancer

Start Date

2024-05-01

Trial ID

NCT06331520

Treatments Being Tested

Netupitant / Palonosetron Oral Capsule [Akynzeo]Olanzapine Dexamethasone Oral

Previous Next